NANOVIRICIDES, INC.

The registrant, a clinical stage biotechnology company, reports in its 10-K Item 1C that as of the filing date, it has not experienced a cybersecurity incident resulting in a material effect on its business strategy, results of operations, or financial condition. The company describes its cybersecurity risk management and governance processes, including reliance on third-party vendors and board oversight.